Results 141 to 150 of about 6,404 (193)

Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy. [PDF]

RMD Open
Winthrop KL, Klaff J, Penn SK, Liu Y, García C, Mysler E, Wells AF, Bu X, Fish I, Chen M, Cunningham AL.   +10 more
europepmc   +1 more source

Cost-effectiveness and public health impact of recombinant zoster vaccine versus no herpes zoster vaccination in selected populations of immunocompromised adults in Canada. [PDF]

BMC Health Serv Res
George S, Carrico J, Hicks KA, Loukov D, Ng C, Curran D.   +5 more
europepmc   +1 more source

Longitudinal single cell profiling of epitope specific memory CD4+ T cell responses to recombinant zoster vaccine. [PDF]

Nat Commun
Wen X, Hu AK, Presnell SR, Ford ES, Koelle DM, Kwok WW.   +5 more
europepmc   +1 more source

Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme. [PDF]

Infect Dis Ther
Hunjan M, Curran D, Marijam A, Vekria Y, Giannelos N.   +4 more
europepmc   +1 more source

A Severe Case of Disseminated Herpes Zoster in a Patient With Crohn's Disease on Upadacitinib Who Completed the Recombinant Zoster Vaccine Series. [PDF]

ACG Case Rep J
Lue N, Burdine L, Kahan T, Reddy K, Nelson R, Lopez C, Lee M, Wolf J.   +7 more
europepmc   +1 more source

Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017-April 2024. [PDF]

Prev Med Rep
Shu Y, Cheng W, He X, Huang L, Chen W, Zhang Q.   +5 more
europepmc   +1 more source